Daily close, T-120 (8/6/24) through T+5. Run-up high $167.38 on 9/17/24, low $142.06 on 1/13/25 (T-120 to T-1). FDA decision 1/21/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 7, 2025, 14 days before the decision date, at-the-money options priced a move of ±3.7% through Jan 24, 2025 (the first listed expiry after the decision; ATM implied volatility 21%). The stock closed +0.8% at the first close across the decision and +4.0% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was SPRAVATO (esketamine) monotherapy approved by the FDA?
Yes. The FDA approved the application for SPRAVATO (esketamine) monotherapy on January 21, 2025. The primary source is linked on this page.
What was SPRAVATO (esketamine) monotherapy under FDA review for?
The application covered Treatment Resistant Depression (TRD4005). The FDA approved the application on January 21, 2025.
How did JNJ stock react to the FDA decision?
On the decision day JNJ moved +0.8%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.